Market
Overview:
Levodopa is a medication and neurotransmitter mainly used for the treatment of
Parkinson's disease and some other extrapyramidal movement disorders. Levodopa
helps relieve many of Parkinson's disease symptoms like rigidity, tremor,
slowness of movement and postural instability. It is used to manage Parkinson's
symptoms and improve mobility and motor impairments. When taken with carbidopa,
levodopa acts directly on the nervous system to increase dopamine levels in the
brain. Levodopa is considered the most effective drug to control symptoms of
Parkinson's disease.
Market Dynamics:
The growth of the levodopa market is majorly driven by increasing prevalence of
Parkinson's disease. Parkinson’s disease is a progressive disorder of the
nervous system affecting millions of people worldwide. According to Parkinson's
Foundation, around 60,000 Americans are diagnosed with Parkinson's each year.
Increasing elderly population is another key factor influencing the market
growth as Parkinson's disease is more common in older age groups. Growing
healthcare expenditure and improving access to healthcare facilities in
developing regions also foster the adoption of levodopa. Additionally, ongoing
pipeline developments and new product launches focusing on controlled release
levodopa formulations further support the market expansion over the forecast
period.
The Global
Levodopa Market Demand is estimated to be valued at US$ 4.77 Bn in 2023
and is expected to exhibit a CAGR of 3.4% over the forecast period 2023 to
2030, as highlighted in a new report published by Coherent Market Insights.
SWOT Analysis
Strength: Levodopa is the primary drug used in the treatment of Parkinson's
disease and has proven efficacy. It provides relief from motor symptoms and
improves quality of life. The rising prevalence of Parkinson's disease is
expected to drive the demand for levodopa over the forecast period.
Weakness: Levodopa has side effects such as nausea, vomiting, low blood
pressure, hallucinations and dyskinesia. These side effects often restrict its
usage and require additional medication. Switching to other alternative
therapies also poses threats to levodopa revenues.
Opportunity: Increasing R&D spending on novel drug delivery systems will
enhance compliance and reduce side effects. Emerging economies with large
disease burden offer significant untapped market potential.
Threats: Alternative non-oral formulations and gene therapies are being
developed which pose a threat to levodopa's market dominance. Societal pressure
to control drug prices can negatively impact revenues.
Key Takeaways
The global levodopa market is expected to witness high growth, exhibiting CAGR
of 3.4% over the forecast period, due to increasing prevalence of Parkinson's
disease. The Parkinson's disease prevalence is estimated to increase from 7
million to over 9 million cases globally between 2015 to 2030. Levodopa is the
most widely prescribed drug for controlling motor symptoms.
Regional analysis: North America dominated the levodopa market in 2020 and is
expected to continue its dominance during the forecast period. This is
attributed to growing prevalence of Parkinson's disease, high healthcare
spending and availability of advanced treatments. However, Asia Pacific is projected
to experience the highest growth rate owing to large patient pools, increasing
healthcare expenditures and growing awareness about treatments.
Key players operating in the levodopa market are Abbott Laboratories, Sun
Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Hikma
Pharmaceuticals PLC, Mylan N.V., Par Pharmaceutical, Inc., Apotex Inc., Sandoz
AG, Dr. Reddy's Laboratories Ltd., Accord Healthcare Ltd. These players are
focusing on developing alternative drug delivery systems such as oral
disintegrating tablets and subcutaneous injections to improve treatment
effectiveness.
For
more insights, Read-
https://www.pressreleasebulletin.com/levodopa-market-trends-size-and-share-analysis/
Comments
Post a Comment